PEPTIDES BIO / QUALITY & DOCUMENTATION
TB-500 and Thymosin Beta-4: Nomenclature, Source Scope and Documentation Review
A research-use-only review of TB-500 and Thymosin beta-4 naming boundaries, a defined actin source, and separate batch documentation.
Research or raw-material evaluation only. Not for human or veterinary use.
Related research material
This article reviews naming, one source record, and documentation practice. Confirm the label and documents for the material actually received before creating a laboratory record.
Research use only. It does not provide human or veterinary use, dosing, administration, safety, or outcome guidance.
Do not turn adjacent names into an identity claim
TB-500 and Thymosin beta-4 can appear together in searches, but a shared research area does not establish that the terms identify the same sequence, preparation, or test article. Preserve the exact name used by a paper and compare it with the label and analytical documents for a received material before linking records.
Defined source: Thymosin beta-4 and actin assembly
Carlier et al. (1996; PMID 8621582) studied Thymosin beta-4 in biochemical actin-assembly experiments. The paper examined G-actin and F-actin interactions, used cross-linking to investigate incorporation into F-actin, and reported concentration-dependent changes in the system. Its results concern Thymosin beta-4 and the stated in vitro conditions.
This source does not identify TB-500 as its test article. It cannot establish that a TB-500 catalogue item is equivalent to the material in the paper, nor can it verify a separately received batch. The distinction is the central finding of this review, not a disclaimer added after a broader claim.
Documentation for the material in hand
Keep the product label, lot identifier, receipt record, and any supplied COA or SDS together. Where a document reports a result, retain the method, result, date, and named lot. A paper about another named material cannot fill missing batch fields.
References
Need a product record?